In particular, the presence of JAK2 mutations in pediatric leukemia cells often confers resistance to traditional chemotherapy, leading to relapse and treatment failure.[9,10] Over the past few years, targeted therapies aimed at inhibiting the JAK-STAT pathway have shown promise in treating various cancers, including hematological malignancies. This evidence concerns the gene SOAT1 and leukemia.